Profile image
Story Views

Last Hour:
Last 24 Hours:

Graves’ Ophthalmopathy -Products under Development by Companies, H2 2016

Friday, January 6, 2017 7:21
% of readers think this story is Fact. Add your two cents.

Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!

The report provides comprehensive information on the therapeutics under development for Graves’ Ophthalmopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graves’ Ophthalmopathy and features dormant and discontinued projects.

Report Highlights:

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

For more information about this report at


- The report provides a snapshot of the global therapeutic landscape of Graves’ Ophthalmopathy

- The report reviews pipeline therapeutics for Graves’ Ophthalmopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Graves’ Ophthalmopathy therapeutics and enlists all their major and minor projects

- The report assesses Graves’ Ophthalmopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Graves’ Ophthalmopathy

Request a sample copy at

Reasons to buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Graves’ Ophthalmopathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Graves’ Ophthalmopathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Key Companies profiles

Genmab A/S

Neothetics, Inc.

Novartis AG

Yuhan Corporation

Ask for Discount at

Few Points from List of Tables

Number of Products under Development for Graves’ Ophthalmopathy, H1 2016 7

Number of Products under Development by Companies, H1 2016 8

Comparative Analysis by Clinical Stage Development, H1 2016 9

Comparative Analysis by Early Stage Development, H1 2016 10

Products under Development by Companies, H1 2016 11

Graves’ Ophthalmopathy – Pipeline by Genmab A/S, H1 2016 12

Graves’ Ophthalmopathy – Pipeline by Neothetics, Inc. , H1 2016 13

Graves’ Ophthalmopathy – Pipeline by Novartis AG, H1 2016 14

Graves’ Ophthalmopathy – Pipeline by Yuhan Corporation, H1 2016 15

Assessment by Monotherapy Products, H1 2016 16

Assessment by Combination Products, H1 2016 17

Number of Products by Stage and Target, H1 2016 19

Number of Products by Stage and Mechanism of Action, H1 2016 21

Number of Products by Stage and Route of Administration, H1 2016 23

Number of Products by Stage and Molecule Type, H1 2016 25

Graves’ Ophthalmopathy Therapeutics – Recent Pipeline Updates, H1 2016 36

Graves’ Ophthalmopathy – Dormant Projects, H1 2016 39

Contact Us:                 
Call: +1-646-491-9876


Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.